Cargando…

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors

BACKGROUND: The INVICTUS trial assessed the efficacy and safety of ripretinib compared with placebo in the management of advanced gastrointestinal stromal tumors. METHOD: We used a Markov model with three health states: progression-free disease, progression disease and death. We parameterized the mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Weiting, Xu, Huiqiong, Hutton, David, Wu, Qiuji, Zhou, Kexun, Luo, Hui, Lei, Wanting, Feng, Mingyang, Yang, Yang, Wen, Feng, Li, Qiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685288/ https://www.ncbi.nlm.nih.gov/pubmed/34938653 http://dx.doi.org/10.3389/fonc.2021.692005

Ejemplares similares

Management of Patients With Advanced Gastrointestinal Stromal Tumor: Emphasis on Fourth-Line Treatment With Ripretinib
por: Brackert, Sandra, et al.
Publicado: (2023)

Ripretinib for gastrointestinal stromal tumours
Publicado: (2021)

Ripretinib for the treatment of advanced gastrointestinal stromal tumor
por: Zalcberg, John R.
Publicado: (2021)

Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review
por: Feng, Mingyang, et al.
Publicado: (2022)

Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward
por: Lostes-Bardaji, M. Julia, et al.
Publicado: (2021)

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
por: Schöffski, Patrick, et al.
Publicado: (2022)

Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors
por: Thirasastr, Prapassorn, et al.
Publicado: (2023)

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
por: Li, Jian, et al.
Publicado: (2022)

Comprehensive analysis of EMT-related genes and lncRNAs in the prognosis, immunity, and drug treatment of colorectal cancer
por: Yang, Yang, et al.
Publicado: (2021)

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report
por: Huang, Shaoqing, et al.
Publicado: (2022)

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study
por: Yang, Weili, et al.
Publicado: (2023)

Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial
por: Huang, Jiaxing, et al.
Publicado: (2018)

Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review
por: Zhang, Yefan, et al.
Publicado: (2023)

The Effects of Autophagy-Related Genes and lncRNAs in Therapy and Prognosis of Colorectal Cancer
por: Yang, Yang, et al.
Publicado: (2021)

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
por: Janku, Filip, et al.
Publicado: (2020)

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
por: Zalcberg, John R., et al.
Publicado: (2021)

Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer
por: Yang, Yang, et al.
Publicado: (2022)

Correction to: Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
por: Bai, Liangliang, et al.
Publicado: (2019)

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021)

Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
por: Bauer, Sebastian, et al.
Publicado: (2022)

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
por: Wu, Qiuji, et al.
Publicado: (2022)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique
por: Wang, Hui-jun, et al.
Publicado: (2021)

Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
por: Janku, F., et al.
Publicado: (2022)

Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience
por: KEFELI, UMUT, et al.
Publicado: (2013)

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives
por: Wu, Qiuji, et al.
Publicado: (2020)

Systemic mastocytosis, in the context of a deleterious germline SDHC variant, treated with ripretinib
por: Saheb Kashaf, Sara, et al.
Publicado: (2023)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique [Corrigendum]
Publicado: (2023)

Gastrointestinal stromal tumor in the fourth portion of the duodenum does not express the CD117: A case report
por: Harhar, Marouane, et al.
Publicado: (2022)

Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
por: Zhang, Xinhua, et al.
Publicado: (2023)

Epidemiology, survival, and costs of localized gastrointestinal stromal tumors
por: Rubin, Jaime L, et al.
Publicado: (2011)

Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors
por: Banerjee, Sudeep, et al.
Publicado: (2020)

Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
por: Zhou, Kexun, et al.
Publicado: (2023)

A rapid and sensitive UPLC-MS/MS method for simultaneous determination of four potential mutagenic impurities at trace levels in ripretinib drug substance
por: Huang, Yiwen, et al.
Publicado: (2022)

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study
por: Zuidema, Sander, et al.
Publicado: (2019)

Transcriptomic study of gastrointestinal stromal tumors with liver metastasis
por: Guo, Jianrong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rrc2ce7ms5vnumf6826aikqiai